Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits

Vaccine

Volumn 34, Issue 38, 2016, Pages 4558-4564

  Choudhry, Azhar ^a   Mathena, Julie ^a   Albano, Jessica D ^b   Yacovone, Margaret ^c   Collins, Limone ^c  

^a Teva Pharmaceuticals   (United States)

^b SYNEOS HEALTH   (United States)

^c Defense Health Agency   (United States)

Author keywords

Adenovirus; Respiratory illness; Retrospective; Surveillance; Vaccination

Indexed keywords

ADENOVIRUS VACCINE;

ADENOVIRIDAE; ADOLESCENT; ADULT; ARMY; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG SAFETY; FEMALE; HEALTH SURVEY; HUMAN; ICD-9; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; RISK; SOLDIER; VACCINATION; ADENOVIRIDAE INFECTIONS; CLASSIFICATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MIDDLE AGED; POSTMARKETING SURVEILLANCE; SENTINEL SURVEILLANCE; UNITED STATES; YOUNG ADULT;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADENOVIRUS VACCINES; ADOLESCENT; ADULT; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; MILITARY PERSONNEL; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; SENTINEL SURVEILLANCE; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84996548607     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.033     Document Type: Article

References (9)

1. [1] Dudding, B.A., Top, F.H. Jr., Winter, P.E., Buescher, E.L., Lamson, T.H., Leibovitz, A., Acute respiratory disease in military trainees: the adenovirus surveillance program, 1966–1971. Am J Epidemiol 97 (1973), 187–198.
2. [2] Hilleman, M.R., Gauld, R.L., Butler, R.L., et al. Appraisal of occurrence of adenovirus-caused respiratory illness in military populations. Am J Hyg 66 (1957), 29–41.
3. [3] Gray, G.C., Goswami, P.R., Malasig, M.D., et al. Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group. Clin Infect Dis 31 (2000), 663–670.
4. [4] Russell, K.L., Hawksworth, A.W., Ryan, M.A., et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999–2004. Vaccine 24 (2006), 2835–2842.
5. [5] Potter, R.N., Cantrell, J.A., Mallak, C.T., Gaydos, J.C., Adenovirus-associated deaths in US military during postvaccination period, 1999–2010. Emerg Infect Dis 18 (2012), 507–509.
6. [6] Radin, J.M., Hawksworth, A.W., Blair, P.J., et al. Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines. Clin Infect Dis 59 (2014), 962–968.
7. [7] Lyons, A., Longfield, J., Kuschner, R., et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 26 (2008), 2890–2898.
8. [8] Kuschner, R.A., Russell, K.L., Abuja, M., et al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine 31 (2013), 2963–2971.
9. [9] Rubertone, M.V., Brundage, J.F., The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 92 (2002), 1900–1904.